Effect of Protein Composition on Gastric Emptying
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00345566|
Recruitment Status : Unknown
Verified June 2006 by Ullevaal University Hospital.
Recruitment status was: Not yet recruiting
First Posted : June 28, 2006
Last Update Posted : June 28, 2006
|Condition or disease||Intervention/treatment||Phase|
|Cerebral Palsy Gastric Dysmotility Enteral Feeding||Procedure: Nutrition composition||Not Applicable|
Several factors in nutrition are known to affect gastric emptying rate, such as energy content, temperature, viscosity etc. In infants the protein composition affects gastric emptying. Children with cerebral pasly commonly have foregut dysmotility - with nausea, vomiting, feeding intolerance and gastroesophageal reflux. Tube feedings, usually based on cows milk are commonly used.
Our hypothesis is that the source and thus protein composition of feeding affects gastric emptying rate and electrofysiology.
Using four different tube feedings, standardized for content of fat, glucose and calories, we will measure gastric emptying rate using C13 octanoic acid as well as electrogastrography will be recorded. The protein modules are derived from casein, whey/casein mixture, hydrolyzed whey and aminoacids. Children with cerebral paresis and gastrostomy will be included. Each serves as his / her own control.
The primary endpoint is gastric emptying rate, the secondary endpoint electrogastrography.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||25 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Effect of the Protein Composition on the Gastric Emptying Rate in Children With Cerebral Paresis|
|Study Start Date :||August 2006|
|Study Completion Date :||December 2007|
- Gastric emptying, measured by octanoic acid breath test.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00345566
|Contact: Groa B Johannesdottir, MDfirstname.lastname@example.org|
|Contact: Charlotte Brun, MDemail@example.com|
|Ullevaal university hospital|
|Oslo, Norway, 0407|
|Study Chair:||Ketil Stordal, PHD|